Objectives: Levodopa (LD) is the most effective antiparkinsonian drug used in the treatment of Parkinson disease (PD). Sex differences in the bioavailability of LD have been shown previously. In addition, epidemiological sex differences in PD have been reported, suggesting an involvement of estrogen. In this study, we evaluated the pharmacokinetics of LD in elderly patients with PD to examine the influence of estrogen.
P arkinson disease (PD) is a rare neurodegenerative disorder. A number of medications consistently improve the clinical symptoms of PD, and levodopa (LD) is considered one of the most effective antiparkinsonian drugs. Understanding the pharmacokinetics of LD is important in the clinical treatment of PD because changes in the pharmacokinetics may affect clinical outcome. 1 Prolonged use of LD is related to motor fluctuations. Motor fluctuations have been shown to be most strongly related to disease duration and the dose of LD, and dyskinesias have been shown to be related to the duration of LD treatment. 2 Although motor fluctuations, such as the wearing-off phenomenon, are thought to result from complex interactions between the kinetic characteristics of LD and progressive changes in the pathophysiology of PD, 3 they may also arise as a result of increased plasma LD concentrations after excessive LD absorption. 4 Therefore, changes in LD pharmacokinetics may influence its clinical effectiveness. Apparent sex differences in LD pharmacokinetics have been shown. 5, 6 When the pharmacokinetics of LD and pramipexole were compared in male and postmenopausal female patients, greater bioavailability was observed only for LD, after adjusting for body weight (BW). 6 In another study, the same sex differences were found in a relatively large cohort. 5 However, the underlying cause for the observed differences is unclear.
The onset age of PD in male patients is approximately 2 years earlier than that in female patients. 7 This sex difference has been suggested to be due to the influence of estrogen. 8 In women, serum estrogen levels drop suddenly at 50 to 60 years of age, which is around menopause. 9,10 Therefore, when assessments of the sex differences in the pharmacokinetics of LD are performed, a separate assessment is needed in the elderly population because the influence of estrogen might possibly be limited. However, there are no reports that have examined this sex difference in elderly patients. Thus, we analyzed the sex differences in the pharmacological parameters of LD in a relatively large group of patients with PD and, in particular, elderly patients with PD.
MATERIALS AND METHODS
A total of 128 PD patients (77 women and 51 men) were enrolled in the study. Written informed consent was obtained from each person, and approval for the study was obtained from the institutional review board. All female patients were at postmenopausal stage. At the time of the examination, the mean (SD) age was 77.9 (6.3) years, the disease duration was 3.2 (2.4) years, the duration of LD treatment was 1.7 (2.0) years, and the Hoehn-Yahr stage was 3.0 (1.2). All of the cases fulfilled the British Brain Bank criteria for the clinical diagnosis of PD. 11 The patients also underwent single-photon emission computed tomography with [ 123 I] N-isopropyl-p-iodoamphetamine as well as brain computed tomography and/or magnetic resonance imaging to exclude atypical or symptomatic parkinsonisms such as progressive supranuclear palsy, multiple system atrophy, vascular disease, and postencephalitis. No patient had a history of a gastrectomy or was on protonpump blocker therapy, which might have reduced gastric acid secretion. None of these patients had a history of hormone (such as estradiol) replacement therapy.
To assess LD pharmacokinetics, the patients were orally given a tablet containing 100 mg of LD and 10 mg of carbidopa (CD) at 9:00 AM after an overnight fast and a medication-free period of at least 18 hours. Blood specimens were collected through an intravenous catheter at 0, 15, 30, 60, 120, and 180 minutes after LD administration, and the plasma LD concentrations were measured by high-performance liquid chromatography with an electrochemical detection system. Separation of the LD was conducted with the alumina adsorption method before the high-performance liquid chromatography procedures. Briefly, 1.0 mL of the plasma sample was mixed with 70 mg of alumina (MP ALUMINA; MP Biomedicals, LLC, Santa Ana, Calif), 1.0 mL of 0.1 M EDTA, and 5.0 mL of 1 M Tris-HCl buffer (pH 8.6) containing 200 μL of 5 μg/mL 3,4-dihydrobenzylamine as an internal standard. After stirring for 15 minutes, the mixture was rinsed 3 times with 10 mL of distilled water. Levodopa was extracted with 200 μL of 0.2 N hydrochloric acid. High-performance liquid chromatography was performed on a system with an autosampler (JASCO International Co, Ltd, Tokyo, Japan) and an Inertsil ODS-3 column (GL Sciences Inc, Tokyo, Japan). The mobile phase consisted of 0.1 mM of sodium phosphate buffer (pH 2.5) containing 5.7% methanol. The flow rate was set at 1.0 mL/min. The electrochemical detection was performed on a Coulochem model 5100A platform with a model 5021 guard cell at 0.38 mV and a model 5011 standard analytical cell at 0.33 mV (Thermo Scientific, Chelmsford, Mass). The coefficient of variation was 1.2% to 7.4% (n = 5), the limit of detection was 0.3 ng/mL, and the limit of quantitation was 1.0 ng/mL. The peak drug concentration (Cmax), the time to attain peak drug concentration (Tmax), the elimination half-life (t 1/2 ), and the area under the curve (AUC) were determined. The AUC was also adjusted by kilogram of BW (AUC/BW), which is presented as the AUC adjusted for BW (AUCw). The Cmax and Tmax were observed values, t 1/2 was determined by a linear regression analysis, and the AUC and the AUCw were estimated from the area under the time-LD concentration graph.
We examined the sex differences in the LD pharmacokinetics with these parameters. In addition, we checked the older subgroup, the late-elderly group (age at examination of 75 years or older; 91 patients, mean [SD] age at examination of 80.8 [4.7] years old), for sex differences. The onset of PD in all of the female patients in this late-elderly group was more than 10 years after menopause.
Because it is not possible to assume a normal distribution for data obtained of all of the parameters, the statistical analyses were performed using a nonparametric method (Mann-Whitney U test). All values were expressed as mean (SD), and statistical significance was set at P < 0.05.
RESULTS
The clinical features of each sex are summarized in Table 1 . There were no statistical differences between the sexes for age at the time of the examination, age at onset, disease severity, disease duration, or duration of LD intake. Body weight was significantly lower in the female patients than in the male patients, and this difference was also observed in the late-elderly group.
The plasma LD concentrations in all 128 patients after LD administration at 0, 15, 30, 60, 120, and 180 minutes were 5.0 ( The plasma LD concentrations in all of the male patients at 0, 15, 30, 60, 120, and 180 minutes after LD administration were 4.9 (2.0), 737 (846), 1201 (916), 868 (460), 615 (283), and 441 (224) ng/mL, respectively, and the plasma LD concentrations in all of the female patients were 5.0 (2.4), 1286 (1102), 1743 (846), 1291 (447), 812 (266), and 499 (219) ng/mL, respectively (Fig. 1A) . The LD concentrations in the female patients were significantly higher than in the male patients at 15, 30, 60, 120, and 180 minutes after LD administration (P = 0.001, P = 0.0005, P < 0.0001, P < 0.0001, and P = 0.039, respectively). The values of various pharmacokinetic parameters in the patients were as follows: AUC: male, 2121 (898); female, 3006 (638) ng/mL per hour (P < 0.0001); AUCw: male, 43.9 (22.6); female, 72.9 (22.4) ng/mL per kilogram per hour (P < 0.0001); Cmax: male, 1475 (886); female, 2192 (775) ng/mL (P < 0.0001); Tmax: male, 48 (46); female, 33 (21) minutes (P = 0.13); and t 1/2 : male, 89 (65); female, 63 (50) minutes (P = 0.04) ( Fig. 2A) .
In the late-elderly subgroup (age at the time of the examination of 75 years or older and age of PD onset of 70 years or older), the plasma LD concentrations of the male patients at 0, 15, 30, 60, 120, and 180 minutes after LD administration were 5.1 (2.0), 690 (888), 1248 (968), 895 (530), 648 (318), and 474 (238) ng/mL, respectively, and the plasma LD concentrations of the female patients were 4.6 (1.7), 1155 (998), 1678 (886), 1326 (456), 847 (289), and 506 (223) ng/mL, respectively (Fig. 1B) . The LD concentrations in the female patients were significantly higher than in the male patients at 15, 30, 60, and 120 minutes after LD administration (P = 0.004, P = 0.008, P < 0.0001, and P = 0.001, respectively). The values for pharmacokinetic parameters in the patients in the late-elderly group were as follows: AUC: male, 2160 (1033); female, 3013 (655) ng/mL per hour (P < 0.0001); AUCw: male, 46.1 (25.7); female, 74.0 (23.0) ng/mL per kilogram per hour (P < 0.0001); Cmax: male, 1462 (925); female, 2152 (756) ng/mL (P = 0.002); Tmax: male, 53 (52); female, 35 (23) minutes (P = 0.22); and t 1/2 : male, 91 (65); female, 65 (49) minutes (P = 0.09) (Fig. 2B ).
DISCUSSION
In this study, sex differences in the pharmacokinetics of LD were observed among all the patients enrolled and in the elderly patients with PD. The AUC and Cmax values were higher in the female subjects compared with the male subjects, and the former had greater LD bioavailability compared with the latter. These results might be related to the sex differences in LD metabolism. The AUCw in the female subjects was almost 1.6 times higher than that in the male subjects. In the analysis of the elderly patient group, the results were the same. Thus, the sex difference in BW was not the only cause of these results. These results were similar to those of previous reports. 5, 6 In this study, there were no situational differences in sex, as shown in the patient profile (see Table 1 ), and we cannot find any obvious reasons for the difference. Estrogen has been reported as one of the factors that is involved in the sex differences in patients with PD. Although the underlying mechanism is not clear, the apparent effects of estrogens on the behaviors that are mediated by the functional modulation of the basal ganglia have been shown in human patients experiencing extrapyramidal disorders. 12 However, the effects of estrogen in PD are still controversial. Some studies have reported that estrogens may induce dopaminergic effects, 13, 14 whereas others report their antidopaminergic effects, as suggested by their improvement of dyskinesias. 15 In an experimental model, it was shown that estrogen can exert substantial effects on striatal dopamine metabolism, specifically in women, and increase neuronal dopamine synthesis and release. 16 However, these effects are solely due to the control of dopaminergic function in the basal ganglia, not involving the peripheral dopaminergic system. Because the sex differences in LD pharmacokinetics that were observed in this study were the result of the peripheral component, it is difficult to implicate estrogen as the main cause of these sex differences. Furthermore, patients who underwent estrogen replacement therapy were excluded from this study. Thus, an explanation for the sex differences in the pharmacokinetics of LD in patients with PD other than based on estrogen must be considered, as suggested previously. 6 Systematic sex differences in basic disease characteristics, motor deterioration, and nigrostriatal degeneration in patients with PD have been reported. 8 In this report, it was suggested that several estrogen status items were associated with the age of onset in patients with PD. The age of onset in women was 2.1 years later than that in men, and the age of onset correlated positively with parity, which is the age of menopause. Furthermore, this study showed that the female subjects had a 16% higher striatal [ 123 I] 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT) binding compared with the male subjects at symptom onset; however, the rate of decline in single-photon emission computed tomography signal did not differ between the sexes. An interpretation of these findings is that the higher striatal initial dopamine content in the female subjects is due to estrogen. In women, the existence of estrogen not only influences disease progression but also produces higher initial striatal dopamine, and this may be related to the sex differences in the onset age of PD. Moreover, parity or fertile life span may influence estrogen status, and this may affect the age of menopause and the onset age of PD. In other words, in female patients with PD, estrogen may preclinically provide a disease-modifying effect through a higher striatal dopamine status. The serum estrogen levels suddenly drop after menopause. 9, 10 The preclinical period of PD is reported to be approximately 7 years. 17 Thus, the effects of estrogen may remain around the age of menopause. When we try to exclude the influence of estrogen as much as possible, sex differences should be evaluated in a more elderly cohort. Therefore, we evaluated the pharmacokinetics of LD in an elderly subgroup (age at onset of 70 years or older in all of the patients). However, a greater bioavailability of LD was also observed. Thus, estrogen alone cannot be the factor that causes the sex differences in the pharmacokinetics of LD in patients with PD.
Another possible reason for the sex differences in the pharmacokinetics of LD could be the altered activity of the catechol-O-methyltransferase (COMT) enzyme. In the presence of decarboxylase inhibitors as in this study, LD mainly metabolizes to 3-O-methyldopa, and COMT acts on this formation. When a COMT inhibitor is added, it produces a longer t 1/2 , resulting in a greater AUC. 18 A sex difference in COMT activity has been reported, 19 and this may explain the greater AUC that was found in the female patients with PD. However, it is known that estrogen has an inhibitory effect on COMT. 20 Indeed, in an analysis of cerebrospinal fluid, the amount of 3-O-methyldopa was lower in patients taking 17β-estradiol than in those taking placebo. 14 Thus, the mechanism underlying the sex difference in COMT activity is complicated, and it may be difficult to consider it a main explanation for the sex differences in the pharmacokinetics of LD.
The tablet used in this study contains LD/CD (100 mg/10 mg), which is standard in Japan; the dose of CD is lower than those in many other countries. The pharmacokinetic profile of LD/CD (100 mg/10 mg) is reportedly close to that of LD/CD (100 mg/ 25 mg), although the bioavailability of LD is slightly higher in the latter. 21 Therefore, the differences in CD dosage might not cause the sex differences.
In this study, a significantly greater bioavailability of LD was found in all female patients with PD and in elderly female patients with PD. Our results suggested that this difference was not only due to BW but also due to sex itself. Body weight has been suggested to influence the pharmacokinetics of LD. 22 The risk for developing dyskinesia is closely linked to LD dose, and the probability of its occurrence markedly increases at doses greater than 4 mg/kg. 23 Thus, it might be useful to adjust LD dosage according to BW to avoid motor complications, such as dyskinesia, in patients with PD. Further, in female patients, a more precise adjustment might be needed.
